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objectives. Proarrhythmic erects have been observed with the 
selective histamine, (Ii,) receptor antagonist drug astemizole, a 
widely prescribed antihistamine. The metabolites of astemizole 
and those of other antihistamine compounds have not heen 
implicated as causative agents of cardiac arrhythmias. The pur- 
pose of this study was to examine whether desmethylastemizole, 
the principal metabolite of astemizole, blocks delayed rectifier 
potassium (K+) channels. 
Eackground. QT interval prolongation and torsade de pointes 
are associated with astemizole intake and have heen ascribed to 
block the repolarizing K+ currents, specifically the rapidly acti- 
vating component of the delayed rectifier iKr. Astemizole under- 
goes extensive tirst-pass metabolism, and its dominant metabo- 
lite, desmethylastemizole, has a markedly prolonged ciimineticn 
time. We report the clinical observation of QT pmlongation and 
torsade de pointes in a patient with undetectable serum concen- 
- 
Astemizole (Hismanal) is a second-generation se!>:!il;e hista- 
mine, (H,) receptor antagonist prescribed for symptomatic 
relief of allergic rhinitis. Several reports of QT interval pro- 
longation and torsade de pointes associated with astemizole 
intake have appeared. The clinical circumstances where this 
plaarrhythmic effect has occurred include exposure to high 
doses of astemizole (l), concomitiml ;Irllli;:.i.“:!tillll (II’ other 
QT prolonging drugs (2,3) and the pr~nrc of a congenitally 
prolonged QT interval (4). The occurrence of QT interval 
prolongation and torsade de pointes with astemizole and other 
selective H, receptor antagonists has been attributed to block- 
ade of potassium (K+) currents (5-7). Specifically, astemizole 
has been demonstrated to block K+ channels that carry P.; 
rapidly activating, delayed rectifier KC current (iKr) (5). 
Although ‘potential proarrhythmic effects have been observed 
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trations of astemizole (<OS rig/ml) and “therapeutic” concentra- 
tinrs of desmethylastemizole (up to 7.7 rig/ml or 173 m&liter). 
&rhods. The perforated patch clamp recording technique was 
used to study the ePects of desmethylastemizole (20 nmollliter) on 
action potentials and iKr in isolated rabbit ventricular myocytes. 
Rmdrs. Desmethylastemizole produced action potential pro- 
longation and the induction of plateau early afterdepolarizations. 
Under voltage clamp conditions, desmethylastemizole suppressed 
iKr amplitude by -65%. The drug E-4031 (100 nmollliter), which 
selectively blocks iKr, had a similar e&t on current amplitude. 
Conclusions. Desmetbylastemizole, the m@or astemizole me- 
taholite. bhks the repolarizing K+ current iKr with high afinity. 
Tbe clinical observation of QT prolongation and torsade de 
pointes found with rstemizole intake may principally he caused by 
the proarrhythrk effects of its metabolite desmethylastemizole. 
(J Am Co8 Cardid 19%;28:1556-61) 
with the parent compound, the mctabolitcs of astcmizolc and 
other antihistamine compounds have not been implicated as 
causative agents of cardiac arrhythmias. 
In this study, we describe a patient who developed QT 
prolongation. recurrent episodes of torsade de pointes and 
cardiac arrest after taking the recommended daily dose of 
aslcmizolc. The arrhythmias were associated with undetectable 
blood concentrations of the parent drug and “therapeutic” 
concentrations of its major metabolite, desmethylastemizole. 
We used these chnical observations to test the hypothesis that 
desmethylastemizole is a potent blocker of iKr. 
Methods 
Clinical data. The patient was admitted to the coronary 
care unit at the University of Wisconsin Hospital and Clinics. 
Continuous telemetry, as well as 124ead surface electrocardio- 
grams (EC&), was digitally recorded on standard equipment 
(Hewlett-Packard). The QT interval was measured to the final 
return of the repolarization wave to baseline from recordings 
obtained at 25 mm/s paper speed. Because the patient was in 
chronic atrial fibrillation and the QT interval is rate depen- 
dent, the QT interval was assessed by measuring the shortest 
and the longest QT intervals from the same ECG limb lead 
(standard ECG lead III) at comparable ventricular rates. QT 
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EXD = early afterdepolarization 
ECG = electrocardiogram, electrocardiographic 
H, = histdmine, 
IC, = concentration for half-maximal drug block 
iKr = dclaycd rcctificr K’ current 
ntetval measurements were made by one of the authors 
(TJ.H.) who had no knowledge of the time and the clinical 
setting of the recording. Routine laboratory data were ob- 
tained through the hospital clinical laboratory. Serum astem- 
izole and desmethylastemizole concentrations were deter- 
mined by a high performance liquid chromatography assay 
utiiizing clectrochcmical detection (National Medical Scrvic- 
es). The lower limit of detection was 0.5 ng/mi for astemizole 
and for its major metabolite, desmethylastemizole. 
Single cell data. Single mbbit venticular cell isoolption pm- 
cedure ‘-;abbit ventricular cells were isolated using the 
method previously developed in this laboratory (8). Briefly, the 
r:tLhits (weighing 2 to 3 kg) were anesthetized with ketamine 
hydrochloride (80 to 100 mg/kg body weight intramuscularly), 
xylazine hydrochloride (3 to 5 mg/kg intramuscularly) and 
sodium pentobarbital(50 mg/kg intravenously) before excision 
of the hearts. The heart was perfused by means of aortic 
cannuiation with normal Tyrode’s soiution for 4 min. This wdb 
followed by 5 min of perfusion with nominally calcium (Cat’)- 
free Tyrode’s solution, and a final perfusion of 8 min with 
Tyrode’s solution containing albumin (1 mg/ml), protease (0.05 
mg/ml) and collagenase (0.6 mg/ml). The ventricles were cut 
into small pieces and incubated in fresh enzyme so!ution 
containing colla.genase (1 mg/ml) and protease (0.1 mglml) for 
10 min at 37°C while being agitated in a shaking water bath. 
The isolated cells were filtered through a nylon mesh (210 pm) 
and stored in a solution contaimng (in mmohliter) 130 potas- 
sium glutamate, 5.7 MgClz, 0.1 EGTA and 10 HEPES. 
Perfomted patch-clamp recording technique. Action poten- 
tials and membrane currents were recorded in whole-cell 
configuration using the amphotericin B-perforated patch 
method as described by Rae et al. (9) (see also Zhou et al. [8]). 
This method minimizes cell dialysis and permits the stable 
recording of membrane currents and cell contraction (8). 
Amphotericin B (60 mg/ml) was dissolved in dimethyl sulfox- 
ide and then added to an internal pipette solution at a final 
concentration of 240 &ml. The internal pipette solution 
contained (in mmovliter) 100 potassium glutamate, 40 KCI, 1.0 
MgC12 and 10 HEPES and was titrated with KOH to pH 7.2. 
Access resistance for voltage clamp experiments was 8 to 
12 MfI. With electronic series resistance compensation (typi- 
cally 70% to 80%) in these cells, the voltage error during peak 
K+ current should be -1 mV. The external solution contained 
(in mmovliter) 137 NaCl, 4.0 KCl, 1.8 C&l,, 1.0 MgCl,, 10 
glucose and 10 HEPES (pH 7.4). A Dagan 3900 patch clamp 
amplifier was used to record action potentials and ionic 
currents. Computer software @CLAMP) was used to generate 
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voltage clamp protocols as well as to record action. potentials’ 
and ionic currents. The data were stored in the computer for 
later analysis. All experiments were performed at 36 +- 1°C. 
Action potentials were recorded using’ then currentclamp 
mode. To study delayed rectifier K+ currents in voltage clamp, 
sodium current was voltage inactivated by holding cells at -40 
or -.5U mV, and L-type calcium current was blocked by adding 
1 pmol!liter nifedipine and IU bmohliter cadmium. 
Drugs. Astemizole and desmethylastemizole were obtained 
from Research Diagnostics Incorporated. The purity of each 
drug was >99.8%. Each drug was dissolved in ethanol to give 
a stock concentration of 10 mmoh’liter. E-4031. which selec- 
tively blocks iKr, was obtained from Eisai Ltd. (Ibaraki, Japan) 
and was dissolved in distilled water to give a stock solution of 
1 mmolllitcr. 
Sratisrical methods. Results are expressed as mean value ? 
SE. Differences between means were evaluated by the use of a 
paired t test or a repeated measures analysis of variance, where 
appropriate. A p value ~0.05 was considered significant. 
Results 
ClinIcal findings. An 81-year old woman presented after 
an episode of rudden collapse at a church meeting. Bystanders 
initiated cardiopulmonary resuscitation, and paramedics, who 
arrived within 8 mitt, found the patient in ventricular fibrilla- 
tioit. She; wz converted with a single 200-J external defibrilla- 
tion jliak to atria1 fibrillation with a moderate ventricular 
response and transported to the hospital in a hemodynamically 
stable condition. Past cardiac history was remarkable for 
chronic atria1 fibrillation and long-standing hypertension. 
Medications on admission included a hydrochlorothiazidc! 
triamterene preparation, digoxin, aspirin and astemizole 
10 mglday on an as-needed basis. Initial laboratory test results 
revealed a serum K+ concentration of 3.6 mEq/liter and a 
magnesium concentration of 1.8 mEq/liter, her electrolyte, 
cardiac muscle enzyme and liver function test results were 
normal. The serum digoxin concentration was 0.7 @ml. The 
ECG on admission showed atria1 fibrillation with a varying 
ventricular response rate (average 88 beats/min) without con- 
duction abnormalities or acute ischemic changes. The QT 
interval ranged from 600 ms (shortest) to 640 ms (longest). 
The patient remained in atrial fibrillation throughout her 
hospital course. During the firs: 48 h of recovety in the 
coronary care unit, several spontaneous episodes of self- 
terminating totsade de pointes were recorded, as shown in 
Figure 1. One episode degenerated into ventricular fibrillation, 
which was promptly defibrillated. At the time of onset of this 
arrhythmia, telemetry monitoring showed the patient to be in 
atria1 fibrillation with an average ventricular response rate of 
84 beats/min, and the measured QT interval over 30 s varied 
between 580 ms (shortest) to 680 ms (longest). The episodes of 
torsade de pointes subsided after the administration of intra- 
venous magnesium sulfate and additional K+ supplementa- 
tion, and by 48 h after admission no further occurrences of 
torsade de pointes were recorded Within 4 days, the patient’s 
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F&ure 1. Tomade de pointes on an electrocardiographic (ECG) 
recurding. The upper trace shows a telemetry strip recording with the 
longest QT measured at 68Q ms. The radial pulse pressure is shown on 
the lower trace. 
mentation had rt.turned to normal from an icitial postarrest 
hypoxic enccphaiopathy. Coronary angiography showed no 
significant coronary artery disease. Echocardicgraphy revealed 
normal systolic ventricular function, increased atrial size, mild 
mitral regurgitation and moderate concentric left ventricular 
hypenrophy. .4t the time of discharge (9 days after admission). 
the QT interval varied from 440 ms (shnrtest) to 560 ms 
(longest) at an alerage ventricular response rate of 90 beats/ 
min. At 3 months’ follow-up, the QT interval recorded on the 
ECG had normalized and varied between 360 ms (shortest) 
and 400 ms ilongest) during atrial iibrillation at an average 
ventricular response rate of 82 beatslmin. 
The history of astemizole intake in this patient prompted 
the determination of parent drug and principal metabolite 
concentrations in bled samples drawn on admission and on 
the fourth day in the hospitai (after spontaneous episodes of 
torsade de pointes had resolved). Neither serum sample con- 
tained a measurable quantity of astemizole. The concentra- 
tions of desmethylastemizole were 7.7 n$nl (17.3 nmovliter) 
on admission and 2.0 @ml on the fourth hospital day. The 
“normal” ranges of steady-state plasma concentrations after a 
IO-mg daily dose of astemizole were 0.1 to 1.4 ne/ml for 
astemizole and 0.8 to 10 rig/ml for desmethylastemizole (10). A 
combined total concentration of more than -20 nglml is 
considered toxic (National Medical Services). 
Patch clamp studies in isolated heart ceils. The effect of 
desmethylastemizole on properties of action potentials was 
studied in isolatcc! r+!+ -ventricular cells. Figure 2 shows 
results from one cell. A control action potential is shown at the 
Btood Pressure 
left. Exposure to 20 nmol’liter of desmethylastemizole resulted 
in the development of action potential prolongation (second 
action potential), followed by the inductiofl of early after- 
depolarizations (EADs) arising from voltages close to the 
action potential plateau (third action potenti,d). Washout of 
desmethylastemizole resulted in the disappearance of EADs 
and the gradual return of action potential properties toward 
control conditions (right action potential). Desmethyl- 
astemizole had no effect on the rest potential (-83.0 2 1.8 mV 
for control, -82.7 2 2.0 mV for cells just before induction of 
the first EAD, n = 5 cells, p : 0.05) or action potential 
amplitude (128.7 + 2.3 mV for control, 130.1 + 1.9 mV for 
cells just before induction of the first vAD, n = 5 cells. p > 
0.05). Under the same conditions, action potential duration at 
50% of repolarization was increased from 273 2 44 ms for 
control conditions to 439 + 49 ms just before the initiation of 
the first EA.D (n = 5 cells. p < 0.05). In these cells, the time 
range required to induce EADs with desmethylastemizole 
exp.dre was 7 to 20 min. In addition to provoking single 
EADs, Lrpmethylastemizole occasionally caused multiple 
EADs before cell repolarization (data not shown). WC also 
studied the parent drug astemizole (10 nmovliter) in two cells. 
At this concentration it resulted in action potential prolonga- 
tion and the induction of platehu EADs (data not shown), 
similar to previous findings of Salata et al. (5). 
Figure 3A shows voltage clamp data obtained with 20 
nmol/iiter of desmethylastemizole. Families of current traces 
from one cell obtained for control conditions and after 12 min 
of exposure to desmethylastemizole are shown in the upper 
part of the figure, with the voltage clamp protocol shown above 
the current traces. In each recording the holding potential ~3s 
-40 mV, and depolarizing steps were applied to voltages 
between -30 and +30 mV at IO-mV increments. For control 
coFIi1Ions, d+&z:L+~ ::cps zc+ated a time-dependent, 
Washout 
Fire 2. Induction of action potential prolongation and 
EADs by desmethylastemizole (DM-AST) in a single 
rabbit myocyte. ‘Ibe cell was stimulated at 0.5 Hz. The 
left a&n potential was recurded in control solution. 
The mtddle action potentials show that desmethylastem- 
‘izole (20 nmollliter) increased action potential duration 
and induced plateau EADL The right action potential 
was recorded after desmethylastemizole washout for 
20 min. 
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outward K’ current that increased in amplitude at more 
positive voitagcs. After the repolarizing step to -40 mV. an 
outward tail current was recorded. Tail current amplitude 
initially increased after more positive depolarizing steps, but 
after voltage steps to + 10, +20 and +30 mV, the K’ currents 
were superimposed. Desmethylastemizole (20 nmovliter) sup- 
pressed both the outward current during depolarizing steps 
and the tail current. Figure 3A also shows current-voltage 
plots of tail current peak amplitude normalized to cell capac- 
itance for six cells. For control conditions (filled circles), the 
threshold for activating delayed rectifier K’ current was close 
to -30 mV, and maximal activation was obtained at voltages 
near +20 mV. In the presence of desmethylastemizole (open 
circles), peak tail current amplitude was significantly reduced 
compared with control conditions after repolarizing voltage 
steps (F, ,.,,S,j = 109. p < 0.001). After the return step from +2Q 
mV, where t&l current amplitude was maximal, desmethy- 
lastemizole reduced the peak current amplitude by 65%. This 
reduction in iKr with desmethylastemizole suggests that it may 
be slightly less potent than astemixole, for which the concen- 
tration for half-maximal drug block (IC,) for blockade of iKr 
is reported io be 1.5 nmol,‘liter (0.7 @ml). Jn three cells, 
washout of desmethylastemizole resulted in the return of tail 
current amplitude nearly to the control level (data not shown). 
Similar findings were obtained using a holding potential of 
-50 mV. 
The delayed rectifier Kf current in rabbit ventricular cells 
is nearly completely suppressed by the experimenid antiar- 
rhythmic drug E-4031, and it rectifies inwardly at veq positive 
voltages, hence it is thought to represent iKr (11-14). To 
confirm this in our experimental model, we studied drug Mock 
by E-4031. Figure 3B shows voltage clamp data obtained with 
100 nmol/liter of E-4031. In the upper part of the figure, 
families of current traces from one cefl are shown for control 
i 
l.ZpA!pF 
-40 -30 -20 -IS 0 10 20 30 mV 
Fire 3. Effect of desmethylastemizole and E-4031 on iKr in rabbit 
ventricular myoqtes. A  sod B, Records of iKr currents recorded in 
control solution and in the presence of 20 nmobliter of desmethyl- 
astemizole (DM-AST [Al) or 100 nmokliter of E-4031 (B). The cells 
were held at -40 or -50 mV and clamped at IO-mV increments to 
voltages between -M) and +.UI m\ (desmethylastemizole) or -30 and 
+20 mV (E-403 I). The current-voltage plots show similar suppression 
of iKr tail current amplitude by desmethylastcmizole and E-4031. 
conditions and after exposure to E-4031. with the voltage 
clamp protocol shown above the current traces. Depolarizing 
steps were applied to voltages between -30 and +20 mV at 
IO-mV increments, and elicited a time-dependent, outward K’ 
current, followed by a tail current after the return step to the 
holding potential. E-4031 (100 nmoVliter) suppressed both the 
outward current during depolarizing steps and the tail current, 
consistent with block of iKr. Figure 3B also shows current- 
voltage plots of tail current amplitude normalized to cell 
capacitance for three cells. When compared with contra1 data 
(filled circles), in the presence of E-4031 (open circles), peak 
tail current amplitude was significantly reduced after repolar- 
izing voltage steps (F!, ?Jj = 100, p < 0.001). After the return 
step from +20 mV, E4031 reduced the peak tail current 
amplitude by 75%. At a higher ~urrceuu&on of 1 ml/liter 
(n = 3 ceils), E-4031 reduced the peak tail current amplitude 
by 95% (data .lot shown). We conclude that the delayed 
rectifier K+ current we recorded has properties similar to iKr, 
as ,reported previously in rabbit ventricular cells (11-13). 
Discussion c 
Therapy with the selective HI receptor antagonists astem- 
izole and terfenadine (Seldane) has been dated with QT 
prolongation and torsade de pointes, usuaUy in the setting of 
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supratherapeutic do& or elevated serum concentrations: The 
clinical ‘findings in this study ‘demonstrate QT prolongation 
with the’induction of torsade de point& and cardiac arrest that 
occurred in the presence of “therapeutic” serum concentra- 
tions of desmethylastemizole and undetectable (CO.5 ngiml) 
serum concentrations of the parent compound. astemizolc. 
Moreover, the results of this stdy demonstrate that desmcthyl- 
astemizole potently blocks iKr, which, in isolated cells. resulted 
in action potential prolongation and induction of EADs. At 20 
nmol/liter, iKr amplitude was reduced by more than 50% The 
drug concentration we studied was similar to the patient’s 
measured serum concentration; thus, desmethylastemrzole 
blocks iKr at concentrations that have been considered thcra- 
peutic. We conclude that this in vitro action of desmethyl- 
astemizole may underlie the proarrhythmic effects we observed 
in vivo. 
Our results are the first to show that desmethylastemizole 
blocks iKr, and they are different from previous findings 
obtained with the H, receptor antagonist, terf’enadine. The 
parent cctmpound, terfenadine. as with astemizole, has been 
shown to block iKr (5,7), whereas the principal metabolite, 
terfenadine carboxylate, is inactive against K’ channels (7). 
Similar findings with terfenadine and its metabolites have been 
reported for cloned K’ channels (15,16). 
In the patient we described, several conditions were present 
that may have favored the devclopmcnt of dcsmcthylastemizole- 
induced long QT syndrome and torsade de pointes. The 
patient was taking a thiazide diuretic and she had a serum K+ 
concertration close to the lower limit of normal (17). The 
presence of left ventricular hypertrophy also may enhance the 
induction of EADs (18). Similarly, atrial fibrillation with 
associated varying cycle lengths and action potential durations 
may predispose the ventricle to the induction of EADs and 
torsade de pointes. The presence of a congenital long QT 
syndrome is unlikely given the normal QT interval on 
follow-up electrocardiography and the Lsence of previous 
ventricular arrhythmic events or sudden death in the patient or 
family members. 
Astemizole is rapidly and completely absorbed after oral 
administration. Three major metaholites (desmethylastem- 
izole, norastemizole and 6-hydroxydesmethylastemizole), 
which are more potent histamine antagonists than astemizole, 
are.gencrated in humans (10,19,20). Of these, desmethylastem- 
izole is the dominant metabolite (10) being produced by 
oxidative demethylation of wtcmizole rhrough the hepatic 
cytochrome P450 system (CYP2D6). Desmethylastemizole 
normally achieves a higher serum concentration than that of 
the parent drug because of extensive first-pass metabolism of 
astemizole (10,21). After a single dose of astemizole, as well as 
after the discontinuation of chronic dosing, the serum 
concentration-time curve of desmethyiastemizole exhibits a. 
hiphasic decay with an initial phase half-life of 1 to 2 days and 
a prolonged terminal phase elimination half-life of -9 to 13 
days (10). Thus, complete elimination of desmethylastemizole 
requires several weeks. The serum concentration-time curve of 
astemizole also exhibits a biphasic decay; however, in contrast 
.to its:desmethyl metabolite, it decays more rapidly with the 
initial half-life of- decay reached within. a ifew hours and a 
terminal elimination phase half-life of I. 1 days (10). 
Clinical implications. There are important clinical impli- 
cations to our findings. Astemizole and terfenadine are com- 
monly prescribed drugs, with over 2.5 million astemizole 
prescriptions filled in I995 in the United States (22). Both 
astemizole and terfenadi,le have been reported to cause QT 
prolongation and torsade de pointes, and both of these com- 
pounds have been shown to block delayed rectifier K’ chan- 
nels. Terfenadine’s metabolites do not block K+ channels; 
thus, it is only the parent compound that is electrophysiologi- 
tally active and has proarrhythmic activity. For astemizole, the 
parent compound and its principal metaholite, dL%ntethyl- 
astemizole, block the delayed rectifier K’ current and induce 
action potential prolongation and EADs, as we have shown. 
Thus, both drugs may contribute to QT prolongation and the 
development of torsade de pointes. However, because of the 
extensive first-pass metabolism of astemizole to dermethyl- 
astemizole, and because of the prolonged elimination time of 
desmethylastemizole, it becomes the predominate circulating 
compound after astemizole administration. The clinical obser- 
vation of QT prolongation and torsade de pointes found with 
astemizole intake may principally be caused by the proarrhyth- 
mic effects of its metabolite, desmethylastemizole. Hence, the 
biotransformation of astemizole into an ~le&ophysiologically 
active metabolite with a long elimination time may he an 
undesirable pharmacologic property. 
Study limitations. In the patient in our report, we cannot 
exclude that some electrophysiologic effects resulted from low 
concentrations of astemizole that were not detected by the 
assay we used. However, because the IC, for astemizole 
blockade of iKr is reported to be 0.7 rig/ml (5), and because the 
patient’s arrhythmias lasted for 48 h and QT prolongation 
persisted for many days, the likelihood that the parent com- 
pound contributed to the patient’s arrhythmias is small. Fi- 
nally, other membrane currents were not studied; therefore, 
additional drug effects cannot be excluded. 
We thank Jonathan Makiclski, MD for thoughtful critique of the manuscript and 
Thomas Havighurst, MS (Department of Biostatistics) for help in the statistical 
analysis of the data. 
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